Industries built on intellectual property - including biotech - generated $11.4 trillion in U.S. GDP last year, 44% of total private-sector output, according to a new USPTO report. Bio.News breaks down what the data shows about biotech's economic and societal value: https://lnkd.in/eYHssEkb
Biotechnology Innovation Organization
Biotechnology Research
Washington, DC 112,310 followers
BIO, Where breakthroughs begin
About us
BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org
- Website
-
https://www.bio.org/careers-bio
External link for Biotechnology Innovation Organization
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Washington, DC
- Type
- Nonprofit
- Founded
- 1993
Locations
-
Primary
Get directions
1201 New York Ave N.W.
Suite 1300
Washington, DC 20005, US
Employees at Biotechnology Innovation Organization
Updates
-
Small and mid-size biotechs, which develop over half of all new drugs, often have no control over what their overseas licensees charge. Bio.News examines why the proposed Globe and Guard pricing models would make it harder for these companies to fund their next innovation. Read more: https://lnkd.in/e7ZkHSvh
-
“Within a week, it was like he was a normal kid,” Ben’s mother says. Karen and Jonathan spent years searching for an answer to what was happening to their son before genetic testing gave them one: LEPR deficiency, caused by a single gene mutation. A clinical trial gave them a path forward. The science behind that moment took years to develop. For Ben, it took days to work. #FightofOurLives. Watch Ben’s story: https://lnkd.in/e3ZAz65d #Biotech #BiotechInnovation
-
50 years of biotech in 50 seconds: In just a handful of decades, American #biotech has advanced from targeting symptoms to offering fundamental cures and broader access for millions across the U.S. Nolan Townsend, CEO of Lexeo Therapeutics, reflects on that shift and what it means for the industry’s next chapter. #Biotech50
-
Thank you to BIO member company Shionogi Inc. (U.S.) for the opportunity to join its quarterly town hall last week. BIO President & CEO John F. Crowley shared his personal journey as a biotech entrepreneur and rare disease advocate and highlighted the critical role companies like Shionogi play in advancing innovation for patients with infectious and rare diseases. John also joined Shionogi President & CEO Nathan Mccutcheon and Senior Executive Officer, Senior Vice President, R&D Supervisory Unit John Keller, for a fireside chat on U.S.-Japan collaboration, AI in drug development, and the future of biotech research. Thank you to the entire Shionogi team for the warm welcome, a great trip, and thoughtful conversations.
-
-
BIO submitted detailed policy recommendations to the Senate on improving patient access to medicines. The focus: PBM reform, eliminating step therapy barriers, and protecting the innovation ecosystem that enables new treatments. Read the full story: https://lnkd.in/eHkKq2Ad
-
Congratulations to Regeneron on FDA approval of Pasatru™, a new treatment option for adults with fibrodysplasia ossificans progressiva that reduces bone formation and flare-ups.
#BreakingNews: The U.S. FDA approved our medicine to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) – an ultra-rare genetic disorder marked by rogue bone formation. This approval is illustrative of our relentless commitment to pushing the boundaries of science to bring transformative therapies to patients and their families, regardless of disease prevalence. We are proud to bring forth a new treatment option for adults with FOP. Read more here: https://bit.ly/4xVJVyR
-
Congratulations to BIO member Ultragenyx on FDA accelerated approval of GENGLYCOS, the first gene therapy to treat the underlying cause of glycogen storage disease type Ia. The approval provides a much-needed first-ever option for adult and pediatric patients eight years and older.
The U.S. FDA has approved the first-ever treatment designed to address the underlying cause of glycogen storage disease type Ia (#GSDIa), a disease that has placed an extraordinary burden on individuals and families managing around-the-clock care to avoid life-threatening drops in blood sugar. As our first gene therapy approval, this milestone also marks a new era in our work to deliver transformative medicines for individuals and families living with rare and ultra-rare diseases. Read the full announcement: https://lnkd.in/gjgkR3m7 #GSD1a
-
Utilization management practices like prior authorization and step therapy create unnecessary barriers to patient access to medicines. CancerCare's Micro Insights, Macro Impact project highlights these barriers through patient stories and empowers patients and caregivers to advocate for change. Read the full story on Bio.News: https://lnkd.in/eypwYpMM
-
This National Immunization Awareness Month (#NIAM), we're highlighting the critical role immunizations play in protecting our communities. Vaccines are one of the safest and most effective tools in modern medicine. They prevent disease, strengthen American's health, and help protect our country. Learn more about the science behind vaccines and why they matter: whywevaccinate.org